會員登入
註冊
BD製藥系統部門宣布前膽性的長期產能擴展計畫，此項計畫主要是滿足甚至是超越現在世界上使用預充填式注射器的需求，包括即將在歐洲設置新的工廠。這項產能擴展計畫將投資超過十二億美元，以充分展現出BD在醫療器材領域的強大領導力和透過藥物傳輸系統致力於引領世界的健康。
此項擴展計畫的目標可滿足目前全世界客戶的需求，並且能滿足突發性的需求像是COVID-19的影響而產生的相關需求。
這項新的擴展計劃將進一步增強BD製藥系統部門的供應鏈網絡，擴增在預充填注射器的生產產能包括針筒和相關的組件，預計2025年的產能將可再增加至14億支以上的預充填式玻璃針筒。
同時利用最先進的生產和運送技術進一步提高產品的品質，增加研發投資，並進一步利用BD公司的創新資源以加速推出新產品和增強產品的功能，關注區域化趨勢並優化至客戶端的生產流程和供應程。
通過這項重大投資，開始轉變BD的整個生產網絡，此目的是使我們的客戶及其所服務的病患，能持續使用BD製藥系統部門所生產的高品質產品。
另外在今年8月，BD台灣宣佈與國光生物科技股份有限公司簽訂合作備忘錄（MOU），這象徵繼雙方多年來的合作之下，未來將會更緊密的交流，合作領域及模式更無限可期，期許雙方結合醫療技術與生產量能以創造更大的價值，為台灣製藥產業創造多元的合作契機。期望借此舉措，推動台灣製藥業的發展並加速與國際藥廠的交流，提升台灣製藥產業的競爭力
此次MOU的戰略合作形式，BD將針對未來有需要委託預充填針筒代工製造的藥廠客戶，介紹予合作夥伴進行代工製造，並且包括製造、檢驗、產品查驗登記等技術相關範疇的支援。
BD announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across its six global manufacturing locations and add a new manufacturing facility in Europe.
The new manufacturing facility in Europe is expected to be operational by the end of 2023. The investment will also fund capacity expansion, new product innovations, manufacturing technology enhancements and business continuity improvements across its existing network, all designed to maximize supply and reduce risks for pharmaceutical companies that rely on ready-to-fill syringes for their injectable drugs — including complex biologics, vaccines and small molecules.
BD invented the ready-to-fill, pre-fillable syringe technology. Since 2018, BD has added 350 million units of manufacturing capacity for glass barrel pre-fillable syringes, and this new commitment will invest in additional upgrades at all of our Pharmaceutical Systems manufacturing facilities and across multiple product categories. In addition, this investment positions BD to have the needed surge capacity for increased pre-fillable syringe demand during times of pandemic response or periods of significant growth of new injectable drugs and vaccines. This significant investment in one of BD's fastest growing business units will further advance our leadership position and enable continued strong growth in the years ahead."
此項擴展計畫的目標可滿足目前全世界客戶的需求，並且能滿足突發性的需求像是COVID-19的影響而產生的相關需求。
這項新的擴展計劃將進一步增強BD製藥系統部門的供應鏈網絡，擴增在預充填注射器的生產產能包括針筒和相關的組件，預計2025年的產能將可再增加至14億支以上的預充填式玻璃針筒。
同時利用最先進的生產和運送技術進一步提高產品的品質，增加研發投資，並進一步利用BD公司的創新資源以加速推出新產品和增強產品的功能，關注區域化趨勢並優化至客戶端的生產流程和供應程。
通過這項重大投資，開始轉變BD的整個生產網絡，此目的是使我們的客戶及其所服務的病患，能持續使用BD製藥系統部門所生產的高品質產品。
另外在今年8月，BD台灣宣佈與國光生物科技股份有限公司簽訂合作備忘錄（MOU），這象徵繼雙方多年來的合作之下，未來將會更緊密的交流，合作領域及模式更無限可期，期許雙方結合醫療技術與生產量能以創造更大的價值，為台灣製藥產業創造多元的合作契機。期望借此舉措，推動台灣製藥業的發展並加速與國際藥廠的交流，提升台灣製藥產業的競爭力
此次MOU的戰略合作形式，BD將針對未來有需要委託預充填針筒代工製造的藥廠客戶，介紹予合作夥伴進行代工製造，並且包括製造、檢驗、產品查驗登記等技術相關範疇的支援。
BD announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across its six global manufacturing locations and add a new manufacturing facility in Europe.
The new manufacturing facility in Europe is expected to be operational by the end of 2023. The investment will also fund capacity expansion, new product innovations, manufacturing technology enhancements and business continuity improvements across its existing network, all designed to maximize supply and reduce risks for pharmaceutical companies that rely on ready-to-fill syringes for their injectable drugs — including complex biologics, vaccines and small molecules.
BD invented the ready-to-fill, pre-fillable syringe technology. Since 2018, BD has added 350 million units of manufacturing capacity for glass barrel pre-fillable syringes, and this new commitment will invest in additional upgrades at all of our Pharmaceutical Systems manufacturing facilities and across multiple product categories. In addition, this investment positions BD to have the needed surge capacity for increased pre-fillable syringe demand during times of pandemic response or periods of significant growth of new injectable drugs and vaccines. This significant investment in one of BD's fastest growing business units will further advance our leadership position and enable continued strong growth in the years ahead."
| 公司名稱 | 新加坡商必帝股份有限公司台灣分公司 |
| 參展產品/ 服務 |
Drug delivery systems. Our offering includes an extensive portfolio of pre-fillable syringes, self-injection systems, safety and shielding solutions. Our products are designed to protect, package and deliver drug therapies and to maximize healthcare worker and patient safety. |
| 網址 | https://drugdeliverysystems.bd.com/ |
| 攤位號碼 | R614 |
